Micro Labs Launches Linapride DM: Affordable Diabetes Treatment in India
Uncontrolled Diabetes has become a major challenge in today's Diabetes Management and it keeps raising the bar. As per the ICMR-INDIAB Study published in Lancet Diabetes Endocrinology 2022, The target HbA1c i.e 7% is achieved only by 36.3% of Diabetes Patients in India. This prompts the dire need for early aggressive combination therapy.
Micro Labs, launches Linapride DM for diabetes patients in India. This medication targets uncontrolled T2DM patients on dual therapy, with or without high-risk comorbid conditions such as cardiovascular disease (CVD), obesity, and chronic kidney disease (CKD).
Approved by DCGI for T2DM management, Linapride DM comes in two dosage strengths: Linapride DM 500 and Linapride DM 1000. Recognizing the economic burden of diabetes Micro Labs is launching Linapride DM at an affordable price, Linapride DM 500 is available at Rs.168 per Strip of 10 tablets while Linapride DM 1000 is available at Rs.178 per Strip of 10 tablets, ensuring all patients have access to essential treatment.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.